High-Purity Reagents for Hereditary Angioedema (HAE) Research, Complement Regulation Studies, and Serpin Mechanism Characterization.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SERPING1/C1 Inactivator drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SERPING1 Recombinant Protein (WT & HAE Mutant Panel) High purity (>95%), Endotoxin <1 EU/μg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View SERPING1 Products |
| Gene Delivery | SERPING1 Promise-ORF / Lentivirus Full-length ORF for stable cell line engineering and gene therapy validation. |
View SERPING1 Products |
| Benchmark Ab | Anti-SERPING1 Recombinant Antibody High-affinity detection clone for PK/PD and ADA assay development. |
View SERPING1 Products |
| Validator | SERPING1 siRNA Set For knockdown and specificity verification in cell-based models. |
View SERPING1 Products |
| Related Target: F12 | Factor XII (F12) Direct protease substrate of SERPING1; essential for contact system inhibition assays. |
View F12 Products |
| Related Target: KLKB1 | Plasma Kallikrein (KLKB1) Downstream effector in the contact activation pathway. |
View KLKB1 Products |
| Related Target: KNG1 | High Molecular Weight Kininogen (KNG1) Bradykinin precursor; central to angioedema phenotype and pathway synergy. |
View KNG1 Products |
| Related Target: BDKRB2 | Bradykinin Receptor B2 (BDKRB2) Downstream effector receptor; comparator for bypass mechanism studies. |
View BDKRB2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Glycosylation Requirements | HEK293 Expressed antigens to preserve native mammalian glycosylation patterns crucial for half-life studies. |
| Serpin Conformational Switching (Active vs. Latent) | HEK293 Expressed Protein with Native Glycosylation; High Purity (>95%) for consistent conformational studies. |
| HAE Mutation Analysis (Functional Characterization) | Disease-Associated Mutants Available (e.g., Common HAE Variants); Sequence Verified; Theoretical MW Confirmed. |
| Cross-Species Translation (Cyno/Mouse) | Human/Mouse/Cyno SERPING1 Orthologs Available with >95% Purity for Preclinical PK/PD Modeling. |
| Protease Specificity Screening | High Purity (>95%) strictly verified by mass spec and SDS-PAGE to ensure accurate stoichiometric inhibition assays. |
| Lack of Reliable Controls | Sequence Verified clinical benchmark antibodies included for baseline assay calibration. |
| False Positives in Knockdown | Sequence-verified siRNA included for precise specificity checks in cell-based models. |
Live SERPING1/C1 Inactivator R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The SERPING1/C1 Inactivator therapeutic landscape is transitioning from plasma-derived replacement therapies to next-generation recombinant and gene therapy modalities. While plasma-derived C1-INH concentrates (Cinryze, Berinert) currently dominate the Hereditary Angioedema (HAE) market, the field is witnessing a paradigm shift toward engineered recombinant proteins (Ruconest) with improved production scalability and reduced infectious risk. Concurrently, AAV-mediated gene therapy approaches aiming to restore endogenous SERPING1 expression are entering preclinical and early clinical phases, promising single-dose curative potential for HAE patients. Beyond HAE, SERPING1 is increasingly recognized as a critical modulator of thromboinflammation in sepsis, ischemia-reperfusion injury, and COVID-19-associated complications, driving expanded indication research.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Plasma-Derived C1-INH | Takeda (Cinryze), CSL Behring (Berinert) | HAE, Acquired Angioedema | Comparative Purity Analysis (Need high-purity recombinant standards) |
| Recombinant C1-INH | Pharming (Ruconest/Rhucin) | HAE (Acute attacks) | Glycosylation Pattern Comparison (Need HEK293-expressed native glycosylation) |
| Gene Therapy (AAV) | BioMarin, Intellia, Various Biotech | HAE (Curative) | Expression Level Quantification (Need validated antibodies and lentivirus controls) |
| Small Molecule Stabilizers | BioCryst, KalVista, Research Phase | HAE Prophylaxis, Inflammatory Disorders | Conformational Stability Assays (Need mutant vs WT protein panels) |
Molecular Differentiation & Assay Strategy
Key Differentiation Factors:
-
Glycosylation Fidelity: SERPING1 contains 13 N-glycosylation sites; sialylation at Asn96 is critical for half-life. Non-human glycosylation (e.g., E. coli or insect cells) leads to rapid clearance. Assay strategy: Lectin blot, sialidase treatment with MW shift analysis, mass spectrometry glycopeptide mapping. TarMart solution: HEK293 expression system ensures humanized glycosylation; theoretical MW standards provided for glycoform validation.
-
Conformational State Control (Active vs. Latent): Serpin family undergoes conformational change via RCL insertion into β-sheet A. Latent SERPING1 has no inhibitory activity; recombinant protein must be in active conformation. Assay strategy: Conformation-sensitive monoclonal antibodies (e.g., only recognizing active conformation) for ELISA; thermal stability analysis (Tm ~56°C for active, ~72°C for latent). TarMart solution: Conformation-specific detection antibodies; lyophilized buffer formulation optimized to prevent spontaneous conversion to latent state.
-
Mutant Functional Profiling: Type I HAE (secretion defect) vs. Type II HAE (functional defect) require different research tools. Common mutations include Ala443Val (affects RCL), Arg444His (P1 site), ΔF305, and Val454Asp. Assay strategy: SPR binding kinetics with C1S or F12a; protease inhibition IC50 determination. TarMart solution: Disease-associated mutant library (e.g., R444C, ΔF305, V454D), sequence verified; active site mutants as negative controls.
-
Cross-Species Reactivity: Preclinical studies require mouse/rat models, but species differences may prevent human SERPING1 from inhibiting rodent proteases. Assay strategy: Cross-inhibition experiments with human/mouse/cyno SERPING1 and species-specific C1S. TarMart solution: Human, mouse, and cynomolgus SERPING1 orthologs with corresponding species-specific C1S proteins.
Recommended Screening Workflow:
- Tier 1: Protein QC: SDS-PAGE (>95% purity), Endotoxin (<1 EU/μg), Mass spec (theoretical MW ~55 kDa, glycosylated ~85-95 kDa).
- Tier 2: Functional Validation: C1S protease inhibition (fluorogenic substrate), F12a contact system inhibition (chromogenic substrate), Heparin binding (heparin affinity chromatography).
- Tier 3: Mechanistic Studies: C1r/C1s complex formation (Native PAGE), Latent state conversion rate (37°C accelerated stability), Polymer formation detection (<5% aggregates).